Sign in Create account

Laurus Labs Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: LAURUSLABS BSE: 540222
₹1980.00
▲ 1.00 (0.05%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
78/100
Strong
Valuation
24/100
Expensive
Momentum
53/100
Neutral

QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations, custom synthesis (CDMO), biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava.

Source: Wikipedia

Key Metrics

Market Capitalization
₹106,969 Cr
PE (TTM)
122.5
Industry median 36.1 (152 companies)
Price to Book
19.7
PEG (TTM)
1.7
Institutions holding %
41.74%
FII + DII, latest filed period
Piotroski Score
8
Relative return vs Nifty50, qtr %
63.5
Relative return vs Sector, qtr %
32.6
Free Cash Flow
₹554 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
83.28%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
71.23%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
15.92%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
83.59%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
22.64%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.33
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.44
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
9.72
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
16.50%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
24.09%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
20.35%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
8.83%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
20.53%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
17.09%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Piotroski F-score is 7 or more (score 8)
  • Yes Debt to equity is below 0.5 (0.44)
  • Yes Return on equity is 15% or more (17.1%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (2.7% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.1%
Low 1955.1000 · High 2001.6000
1W return
-2.7%
Low 1955.1000 · High 2055.3000
1M return
3.4%
Low 1811.7000 · High 2055.3000
52W return
127.1%
Low 843.0000 · High 2055.3000
Lifetime High ₹2034.0000 (Sept. 23, 2026)
Lifetime Low ₹259.5000 (Nov. 10, 2020)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish4
Bearish2
5D
1992.3
10D
1986.0
20D
1956.5
50D
1847.2
100D
1675.0
200D
1348.2

Delivery and volume

Day avg. delivery
46.3%
Week avg. delivery
52.9%
Month avg. delivery
53.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1978.90
Pivot
First resistance2002.70
Second resistance2025.40
Third resistance2049.20
First support1956.20
Second support1932.40
Third support1909.70
Day RSI58.1
Day MFI57.2
Day MACD44.55
Day MACD signal49.11

Beta

1M0.37
3M0.59
1Y0.80
3Y0.99

Price change analysis

↑ 3.4%
Over 1 Month
LowHigh
1811.702055.30
↑ 32.6%
Over 3 Months
LowHigh
1448.202055.30
↑ 90.6%
Over 6 Months
LowHigh
994.252055.30
↑ 127.1%
Over 1 Year
LowHigh
843.002055.30
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 122.5 (own history: 66.5–130.2)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹1,757 Cr
Net profit (June 30, 2026)
₹290 Cr
Basic EPS (June 30, 2026)
₹5.3700

Ranks #6 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter27.47%
  • Mutual funds10.15%
  • FII/FPI28.00%
  • Other DII3.59%
  • Public30.79%

Largest holders

NameCategoryShares %Shares
M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava)Promoter22.9800%124126740
MIRAE ASSET LARGE & MIDCAP FUNDPublic4.3300%23387661
NEW WORLD FUND INCPublic4.2800%23106395
ANUKAR PROJECTS PRIVATE LIMITEDPublic3.2400%17483610
SMALLCAP WORLD FUND, INCPublic2.7700%14947573

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 27.49% to 27.47% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 25.82% to 28.00% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 11.22% to 10.15% in Jun 2026 qtr

33 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 568 insider trades, 17 SAST, 39 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
10 Dec 2024 PRATHIMA CHAVA Other Pledge 0 ₹11.53 Cr
30 Oct 2023 G. SREELAKSHMI Immediate relative Sell 0 ₹0
24 Mar 2022 Venkata Jayasree Kumari Tadikonda Immediate relative Buy 0 ₹0
24 Mar 2022 Venkata Jayasree Kumari Tadikonda Immediate relative Buy 0 ₹0
24 Mar 2022 Venkata Jayasree Kumari Tadikonda Immediate relative Buy 0 ₹0
1 Mar 2022 YAMINI TANGUTURI Immediate relative Sell 0 ₹0
1 Mar 2022 MADHURI MEDASANI Immediate relative Buy 0 ₹0
18 Dec 2021 Chandra kumari Immediate relative Pledge 0 ₹51.74 L
20 Sep 2021 VIJAYA KUMARI SURYADEVARA Immediate relative Sell 0 ₹0
9 Sep 2021 SREELAKSHMI GOGIREDDY Immediate relative Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 77 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
31 Aug 2026 SOCIETE GENERALE Bulk Sell 2,810,437 1903.8400 NSE
31 Aug 2026 INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. Bulk Buy 1,718 1922.6900 NSE
31 Aug 2026 INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. Bulk Sell 5,134,361 1914.0400 NSE
31 Aug 2026 BNP PARIBAS FINANCIAL MARKETS Bulk Buy 15,399 1860.3500 NSE
31 Aug 2026 BNP PARIBAS FINANCIAL MARKETS Bulk Sell 6,272,175 1914.2800 NSE
27 Jan 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 3,690,709 536.5000 NSE
27 Jan 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 3,689,009 536.2300 NSE
14 Mar 2023 CYBAGE SOFTWARE PRIVATE LIMITED Block Sell 635,894 305.0000 NSE
14 Mar 2023 ARUN VIJAY NATHANI Block Buy 635,894 305.0000 NSE
25 Oct 2022 ISHARES INDIA SC MAURITIUS COMPANY Block Sell 210,010 479.8000 BSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
24 Jul 2026 Financial Results Yes
30 Apr 2026 Financial Results/Dividend Yes
23 Jan 2026 Financial Results Yes
23 Oct 2025 Financial Results/Dividend Yes
25 Jul 2025 Financial Results Yes

Corporate Announcements

All 4 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Insider Trading / SAST Laurus Labs Ltd - 540222 - Closure of Trading Window
18 Sep 2026 Company Update Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
15 Sep 2026 Company Update Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10 Sep 2026 Company Update Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (22.6%)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • PE above 35 (122.5) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.

Part of: NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY MIDCAP 100, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY MIDCAP 50, NIFTY PHARMA, NIFTY PHARMA

Frequently asked questions about Laurus Labs Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.